MDCO News and Press, The Medicines Company From 11/18/19

The Medicines Company (NASDAQ: MDCO ) is up  2%  premarket on light volume in reaction to positive results from a Phase 3 clinical trial, ORION-10 , evaluating inclisiran, dosed twice per year, in patients with atheroslerotic cardiovascular disease and elevated low-density lipop...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 11/14/2019. Please visit our Tracking David Einhorn's Greenlight Capital Hol...

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver ...

This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...

On their recent conference call for The Medicines Company ( MDCO ), management highlighted the power of Inclisiran’s profile and likelihood of its potential to change the paradigm of ASCVD (atherosclerotic cardiovascular disease) treatment, notes biotech expert John McCamant ...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

ORION-10 presentation on November 16 and ORION-9 presentation on November 18 Company also to sponsor educational sessions throughout AHA annual meeting Company to host investor conference call and webcast on Monday, November 18, 12:00 pm EST, to discuss results of studies The...

Image source: The Motley Fool. Medicines Co   (NASDAQ: MDCO) Q3 2019 Earnings Call Oct 30, 2019 , 8:30 a.m. ET Operator Continue reading

The Medicines Company (MDCO) Q3 2019 Earnings Conference Call October 30, 2019 8:30 AM ET Company Participants Krishna Gorti - Vice President of Investor Relations Mark Timney - Chief Executive Officer Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Develo...

- Inclisiran’s pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints - Phase 3 data reinforced durable, potent efficacy and excellent safety - ORION-11 results presented at ESC Congress 2019 ...